262 related articles for article (PubMed ID: 36326285)
1. Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.
Lipsky AH; Lamanna N
Cancer; 2023 Jan; 129(1):18-31. PubMed ID: 36326285
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
3. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
4. First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
Cherng HJ; Jain N
Hematol Oncol Clin North Am; 2021 Aug; 35(4):725-738. PubMed ID: 34174983
[TBL] [Abstract][Full Text] [Related]
5. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
6. Dual-targeted regimens for the frontline treatment of CLL.
Ujjani C
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):421-426. PubMed ID: 38066921
[TBL] [Abstract][Full Text] [Related]
7. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
8. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
9. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
Islam P
Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
[TBL] [Abstract][Full Text] [Related]
10. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
Hanna KS; Fijalka A; Watson I; Brown O; Ojulu A
J Oncol Pharm Pract; 2022 Dec; 28(8):1869-1884. PubMed ID: 35635742
[TBL] [Abstract][Full Text] [Related]
12. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Odetola O; Ma S
Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
[TBL] [Abstract][Full Text] [Related]
13. Frontline Therapy in Chronic Lymphocytic Leukemia.
Arguello-Tomas M; Albiol N; Moreno C
Acta Haematol; 2024; 147(1):47-59. PubMed ID: 37899041
[TBL] [Abstract][Full Text] [Related]
14. First line therapy of CLL.
Hallek M
Hematol Oncol; 2023 Jun; 41 Suppl 1():129-135. PubMed ID: 37294974
[TBL] [Abstract][Full Text] [Related]
15. Sequencing and combination of current small-molecule inhibitors for chronic lymphocytic leukemia: Where is the evidence?
Chung C; Umoru G; Abboud K; Hobaugh E
Eur J Haematol; 2023 Jul; 111(1):15-28. PubMed ID: 37037657
[TBL] [Abstract][Full Text] [Related]
16. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia.
Guru Murthy GS; Atallah E
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):346-350. PubMed ID: 37363977
[TBL] [Abstract][Full Text] [Related]
18. Current Perspectives on Therapy for Chronic Lymphocytic Leukemia.
Awan FT; Al-Sawaf O; Fischer K; Woyach JA
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-10. PubMed ID: 32239979
[TBL] [Abstract][Full Text] [Related]
19. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
Bennett R; Anderson MA; Seymour JF
J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
[TBL] [Abstract][Full Text] [Related]
20. Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.
Banerji V; Aw A; Robinson S; Doucette S; Christofides A; Sehn LH
Curr Oncol; 2020 Dec; 27(6):e645-e655. PubMed ID: 33380880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
